Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2006 | Original Paper

Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)

Authors: W. Stöhr, M. Paulides, I. Brecht, A. Kremers, J. Treuner, T. Langer, J.D. Beck

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2006

Abstract

Purpose: Up to now, cardiotoxicity of epirubicin has been studied almost exclusively in adult cancer patients. The aim of this study was to investigate epirubicin in children and adolescents, in comparison with doxorubicin. Methods: About 172 soft tissue sarcoma patients (mean age at diagnosis: 8.3 years), treated with epirubicin (median cumulative dose: 450 mg/m²) or doxorubicin (median cumulative dose: 240 mg/m²) within the high-risk group of the CWS-96 study, were examined in a prospective multicentre study. Heart function was analysed by echocardiography, measuring left-ventricular fractional shortening (FS). The median follow up was 27.7 months. Results: Incidence of clinically manifest cardiomyopathy was 0% (0/60; 95% CI: 0–6.0%) in patients treated with epirubicin, and 0.9% (1/108; 95% CI: 0–5.1%) in patients treated with doxorubicin. A further three patients showed subclinical cardiomyopathy. There was no difference in FS between the two treatment arms. Conclusions: Cardiotoxicity was low in our study. For the short term, cardiotoxicity seems to be only a minor problem in patients treated with epirubicin as applied in this cohort.

Alderton PM, Gross J, Green MD (1992) Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 52:194–201PubMed

Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R,Valagussa P (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359–369PubMed

Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavere P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I (2004) Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22:3070–3079CrossRefPubMed

Bossi G, Lanzarini L, Laudisa ML, Klersy C, Raisaro A, Arico M (2001) Echocardiographic evaluation of patients cured of childhood cancer: a single centre study of 117 subjects who received anthracyclines. Med Pediatr Oncol 36:593–600CrossRefPubMed

Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70:261–266PubMed

Bu’Lock FA, Mott MG, Oakhill A, Martin RP (1995) Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 73:340–350PubMedCrossRef

Bu’Lock FA, Mott MG, Oakhill A, Martin RP (1996) Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 75:416–422PubMed

Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A, Louis P, Wolf JE, Brunotte F (1998) Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 21:665–670PubMedCrossRef

Dardir MD, Ferrans VJ, Mikhael YS, el-Grindy MS, el-Aasar AB, el-Zawahry HM, Alling DW, Banks SM, el-Mawla NG (1989) Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 7:947–958PubMed

Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17:3596–3602PubMed

Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D’Angio GJ, Breslow NE (2001) Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study group. J Clin Oncol 19:1926–1934PubMed

Hausdorf G (1993) Late effects of anthracycline therapy in childhood: evaluation and current therapy. In: Bricker JT, Green DM, D’Angio GJE (eds) Cardiac toxicity after treatment for childhood cancer. Wiley–Liss, New York Chichester Brisbane Toronto Singapore, pp 73–85

Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, et al (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818–26PubMed

Jakacki RI, Larsen RL, Barber G, Heyman S, Fridman M, Silber JH (1993) Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer 72:2739–2745

Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniels O (2000) Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 26:1099–1108CrossRefPubMed

Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191–196PubMed

Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA (2002a) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819–829CrossRef

Kremer LCM, van Dalen EC, Offringa M, Voute PA (2002b) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13:503–512CrossRef

Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E (1991) Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 46:301–305PubMedCrossRef

Langer T, Henze G, Beck J (2000) Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 34:348–351CrossRefPubMed

Langer T, Stohr W, Bielack S, Paulussen M, Treuner J, Beck JD (2004) Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42:373–379CrossRefPubMed

Langer T, Stohr W, Paulides M, Kremers A, Dorr HG, Gobel U, Beck JD (2005) Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS). Klin Padiatr 217:176–181CrossRefPubMed

Lanzarini L, Bossi G, Laudisa ML, Klersy C, Arico M (2000) Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J 140:315–323CrossRefPubMed

Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73–77CrossRefPubMed

Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood (see comments). N Engl J Med 324:808–815PubMedCrossRef

Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Schluchter MD, Colan SD (2001) Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. Circulation 104:310–316PubMed

Marx M, Langer T, Graf N, Hausdorf G, Stohr W, Ludwig R, Beck JD (2002) Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No. 9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol 39:18–24CrossRefPubMed

McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K (1983) Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048–1056CrossRefPubMed

Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van Den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753PubMed

Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, Hansen M (1990) Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806–1810PubMed

Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ (1991) A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148–2152PubMed

Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502–3508PubMed

Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I (1997) Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 15:61–68PubMed

Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I (1995) Cardiac function in Wilms’ tumor survivors. J Clin Oncol 13:1546–1556PubMed

Steinherz L, Wexler L (1998) The prevantion of anthracycline cardiomyopathy. Prog Pediatr Cardiol 8:97–108CrossRef

Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics 89:942–949PubMed

Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677CrossRefPubMed

Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW, Hannigan JF, Meyers FJ, Mitchell EP, et al (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46:3722–3727PubMed

Title: Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)
Authors: W. Stöhr
M. Paulides
I. Brecht
A. Kremers
J. Treuner
T. Langer
J.D. Beck
Publication date: 01-01-2006
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2006
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-005-0041-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Cancer-associated loss of TARSH gene expression in human primary lung cancer

Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Expression of apoptosome pathway-related transcripts in non-small cell lung cancer

Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer

Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page